Short Interest in Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) Drops By 7.2%

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD - Get Free Report) was the target of a large decline in short interest in the month of September. As of September 30th, there was short interest totalling 18,000 shares, a decline of 7.2% from the September 15th total of 19,400 shares. Based on an average daily volume of 32,500 shares, the days-to-cover ratio is presently 0.6 days. Approximately 3.2% of the shares of the company are sold short.

Cadrenal Therapeutics Price Performance

Shares of NASDAQ CVKD traded up $0.95 during midday trading on Thursday, hitting $16.30. 100,628 shares of the company's stock traded hands, compared to its average volume of 24,628. The stock has a market capitalization of $260.93 million, a PE ratio of -52.58 and a beta of 1.81. The company has a fifty day moving average price of $10.62. Cadrenal Therapeutics has a 1 year low of $5.40 and a 1 year high of $32.55.

Cadrenal Therapeutics (NASDAQ:CVKD - Get Free Report) last announced its earnings results on Wednesday, August 7th. The company reported ($33.75) EPS for the quarter, beating analysts' consensus estimates of ($285.60) by $251.85. On average, analysts predict that Cadrenal Therapeutics will post -6.72 EPS for the current year.

Cadrenal Therapeutics Company Profile

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome.